Table 2.

Cohorts, doses, toxicities, and dose interruptions and reductions

Cohort1233STotal
N567624
Dosing schema
 Talazoparib (PO) mg/day0.75111 (2/3 weeks)
 Carboplatin AUC (i.v.)1.5 (2/3 weeks)1.5 (2/3 weeks)1.5 (3/3 weeks)1.5 (3/3 weeks)
Toxicity all grades
 Neutropenia4; 80%4; 66.67%3; 50%6; 100%17 (71%)
 Anemia3; 60%6; 100%6; 85%6; 100%21 (88%)
 Thrombocytopenia2; 40%5; 83%5; 71%5; 83%19 (79%)
 Fatigue4; 80%5; 83%4; 57%1; 17%14 (58%)
Toxicity grade 3/4
 Neutropenia4; 80%4; 66.67%1; 14.2%6; 100%15 (62.5%)
 Anemia3; 60%03; 42.8%3; 50%9 (37.5%)
 Thrombocytopenia1; 20%1; 16.67%1; 14.2%4; 66.67%7 (29%)
 Fatigue02; 33.3%1; 14.2%03 (13%)
DLT1: G3 Fatigue1: G4 Thrombocytopenia2 (8%)
Dose delivery
 Dose reduction350512 (50%)
 Dose interruptions355618 (75%)
Transfusions/growth support
 RBC transfusion20417 (29%)
 Filgrastim use24015 (21%)
  • Abbreviation: DLT, dose-limiting toxicity; IV, intravenous; N, number of patients; PO, orally; RBC, red blood cell.